ACS, Ovarian Cancer Research Alliance form research collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Cancer Society and Ovarian Cancer Research Alliance partnered to fund multidisciplinary research projects to explore new ways of detecting, treating, and preventing ovarian cancer relapse and for improving quality of life among those diagnosed with ovarian cancer.

The two organizations are committing to a total investment of $8 million to sustain four research teams over four years.

The joint initiative seeks to raise funds to support four multidisciplinary research teams to investigate biological, clinical, and psychosocial factors associated with ovarian cancer outcomes. Once initial funding is acquired, a request for proposal/critical peer review process will select the four research teams.

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login